Evidence Table D-16. Institutionalization outcomes in studies comparing interventions to prevent development of delirium

| Author, year | Population | Intervention group | Control group | Route of administration | Outcome definition | n / N (%), intervention group | n / N (%), control group | Relative risk (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Schrijver, 2018[12](#_ENREF_12) | Medical and surgical patients | Haloperidol (Planned dose: 1mg) | Placebo | Oral | New institutionalization | 13 / 118 (18.3%) | 8 / 124 (11.9%) | 1.71 (0.73 to 3.97) |
| Schrijver, 2018[12](#_ENREF_12) | Medical and surgical patients | Haloperidol (Planned dose: 1mg), | Placebo | Oral | Not applicable | 7 / 118 (6.1%) | 6 / 124 (5%) | 1.23 (0.42 to 3.54) |
| Schrijver, 2018[12](#_ENREF_12) | Medical and surgical patients | Haloperidol (Planned dose: 1mg) | Placebo | Oral | New institutionalization | 10 / 118 (16.1%) | 8 / 124 (11.9%) | 1.31 (0.54 to 3.21) |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Larsen, 2010[9](#_ENREF_9) | Post-operative elderly joint replacement surgery patients | Olanzapine (Planned dose: 5mg) | Placebo (Planned dose: 5mg) | Oral | Discharge to rehabilitation facility (SNF or acute [hospital-level]) care | 116 / 196 (59.2%) | 143 / 204 (70.1%) | 0.84 (0.73 to 0.98) |

CI=confidence interval; ICU=intensive care unit; mg=milligram; MV=mechanical ventilation; n=sample size; SNF=skilled nursing facility